pre-update Archives

Announcement

Ghent University wins the 2021/22 Certara-Simcyp Grant and Partnership Scheme

PRINCETON, N.J., January 9, 2023 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation,…

CertaraJanuary 9, 2023

White Paper

Drug interactions with therapeutic proteins, regulatory expectations and modeling and simulation approaches

CertaraJanuary 3, 2023

Blog

New FDA Requirement to Support Labeling on DDIs in the Pediatric Population

The effects of drug-drug interactions (DDIs) could differ in the pediatric population compared to adults.…

CertaraDecember 21, 2022

Blog

The Phoenix Workflow Shortcuts Every Pharmacokineticist Needs

Certara’s Phoenix™ Pharmacokinetic and Pharmacodynamic (PK/PD) Platform can revolutionize your pharmaceutical organization’s approach to PK/PD…

CertaraDecember 16, 2022

Press Release

Certara Announces the Completion of Arsenal Capital Partners’ Investment and the Appointment of David Spaight to the Board of Directors

Arsenal closed the previously announced $449M stock purchase from funds controlled by EQT Private Equity…

CertaraDecember 8, 2022

On-Demand Webinar

Therapeutic Proteins’ Drug-Drug Interactions: Updates & Challenges

Therapeutic proteins (TP) - and more specifically monoclonal antibodies - are part of the therapeutic…

CertaraDecember 5, 2022

Brochure

BaseCase Portal

CertaraNovember 30, 2022

Press Coverage

Project Optimus: How to Prepare for Success

For some time now, cancer drug developers have known “Project Optimus” and new dose optimization…

CertaraNovember 28, 2022

White Paper

The eCTD Submission Process: Tips and Tricks for Drug Development Success

Our experts compiled the tips and best practices you need to know for a successful…

CertaraNovember 22, 2022

Blog

Tips & Tricks for Data Management in Phoenix WinNonlin

Learn some tips & tricks for the Data Wizard, a data management tool in Phoenix,…

CertaraNovember 18, 2022

pre-update

Ghent University wins the 2021/22 Certara-Simcyp Grant and Partnership Scheme

Drug interactions with therapeutic proteins, regulatory expectations and modeling and simulation approaches

New FDA Requirement to Support Labeling on DDIs in the Pediatric Population

The Phoenix Workflow Shortcuts Every Pharmacokineticist Needs

Certara Announces the Completion of Arsenal Capital Partners’ Investment and the Appointment of David Spaight to the Board of Directors

Therapeutic Proteins’ Drug-Drug Interactions: Updates & Challenges

BaseCase Portal

Project Optimus: How to Prepare for Success

The eCTD Submission Process: Tips and Tricks for Drug Development Success

Tips & Tricks for Data Management in Phoenix WinNonlin

Newsletter sign up

Quick links

Solutions

Contact